Last updated 2026-07-24
TL;DR
Sermorelin is a 29-amino-acid GHRH analog with a real FDA history (sold as Geref until it was discontinued for business reasons, not safety). CJC-1295 is a longer-acting GHRH analog, often paired with a GHRP, that has never been FDA-approved for human use. Sermorelin has more clinical data and a shorter, more predictable action; CJC-1295 lasts longer but carries more regulatory and sourcing uncertainty.
What is the difference between CJC-1295 and sermorelin?
Both are synthetic analogs of growth hormone releasing hormone (GHRH), the hypothalamic signal that tells the pituitary gland to make and release growth hormone. That's where the similarity mostly ends. Sermorelin is a 29-amino-acid fragment of human GHRH (GHRH 1-29), which happens to be the shortest sequence that keeps full biological activity [1]. It has a short half-life, on the order of 10 to 20 minutes, so it mimics the body's natural pulsatile GH release pattern fairly closely. It was studied for years under the brand name Geref, approved by the FDA in the early 1990s for diagnostic and pediatric growth hormone deficiency use, and later discontinued as a commercial product, not pulled for a safety problem [2]. CJC-1295 is a modified, longer-acting GHRH analog. The original research version (sometimes called CJC-1295 with DAC, for Drug Affinity Complex) binds to albumin in the blood and extends its half-life to several days [3]. A shorter version without DAC, often just called "CJC-1295" or confusingly sold under that name even though it behaves more like a modified GHRH 1-29 fragment (mod GRF 1-29), has a half-life closer to 30 minutes. Neither version has FDA approval for any human use. Both exist almost entirely in the research-chemical and compounded-peptide markets in the US. In plain terms: sermorelin is the older, better-documented, shorter-acting option with a real prescription drug history. CJC-1295 is the newer, longer-acting, less-studied option that was built in a lab to solve a dosing inconvenience, not a safety or efficacy problem.
How does each one work in the body?
Both peptides work upstream of growth hormone itself. Instead of injecting GH directly, they push on the pituitary gland's own GHRH receptor, prompting it to release GH in a pulse. Sermorelin's short half-life means it produces one clean pulse of GH release, then clears out of the system quickly. This is closer to how endogenous GHRH behaves physiologically, and it's part of why it was originally studied as a diagnostic tool for GH deficiency, a rapid stimulation test rather than a slow drip [1]. CJC-1295 (with DAC) is built to stay in circulation, continuously nudging the pituitary rather than giving one discrete pulse. Proponents describe this as a steadier GH elevation. Critics point out that continuous, non-pulsatile stimulation isn't how the body normally does it, and there isn't strong long-term human data on what that difference means over months or years of use. Some protocols pair CJC-1295 with a growth hormone releasing peptide (GHRP) like ipamorelin, on the theory that the two work through separate receptor pathways (GHRH receptor vs. ghrelin/GHS receptor) and produce a bigger combined pulse. That combination approach has more market buzz than it has controlled clinical trial data behind it.
Which one has stronger clinical evidence?
Sermorelin wins here by a wide margin, mostly because it had an actual FDA approval pathway. Geref (sermorelin acetate) went through FDA review and was approved for diagnostic testing of growth hormone secretion and, in an injectable form, for treatment of growth hormone deficiency in children [2]. That means there's a real package insert, real dosing studies, and real pharmacokinetic data on file, even though the branded product is no longer marketed in the US. CJC-1295 has never gone through that process. Most of what exists is early-phase pharmacology research, including a placebo-controlled study of single and multiple doses in healthy adults that found sustained increases in GH and IGF-1 with CJC-1295 [3]. That's useful mechanistic information, but it is not the same as an approved drug with post-market surveillance. The FDA has also flagged compounded CJC-1295 and similar peptides as substances that don't meet the bar for legal compounding because they aren't components of an FDA-approved drug and lack established safety and efficacy data for that use [4]. If you're the kind of person who wants to see the paper trail before you put something in your body, sermorelin has one. CJC-1295 mostly doesn't, at least not one that's gone through independent regulatory review.
CJC-1295 vs sermorelin: side-by-side comparison
| Feature | Sermorelin | CJC-1295 | |
|---|---|---|---|
| Structure | GHRH 1-29 fragment | Modified GHRH analog, sometimes with DAC | |
| Half-life | Roughly 10-20 minutes [1] | ~30 min (no DAC) to several days (with DAC) [3] | |
| FDA history | Approved as Geref, later discontinued commercially, not for safety [2] | Never FDA-approved for human use | |
| Typical use pattern | Nightly subcutaneous injection | Every-other-day to twice-weekly injections (DAC version) | |
| Clinical data volume | Established diagnostic and pediatric GHD studies | Limited early-phase pharmacology studies | |
| Regulatory status for compounding | Historically compounded from an approved drug's active ingredient | FDA has raised concerns about compounding legality [4] | |
| Common combination | Sometimes with GHRPs (ipamorelin, GHRP-2/6) | Frequently marketed alongside ipamorelin | The practical read: sermorelin is the conservative, better-documented choice. CJC-1295 offers dosing convenience (fewer injections, especially with DAC) at the cost of a much thinner evidence base and murkier legal footing. |
Sermorelin vs HGH: which is the better choice?
This is usually the real question underneath "CJC vs sermorelin," so it's worth answering directly and honestly. Sermorelin and HGH are not interchangeable in mechanism. HGH (somatropin) is the hormone itself, injected directly, bypassing the pituitary gland entirely. Sermorelin is a signal that asks your own pituitary to make and release GH. If someone's pituitary is healthy and capable of responding, sermorelin can raise GH and IGF-1 levels, though generally to a more modest, physiologic degree than direct HGH injection [5]. If the pituitary is damaged or non-functional, sermorelin won't work well, because there's no gland left to respond to the signal. HGH has a much larger and more rigorous evidence base for specific FDA-approved indications: pediatric growth failure, adult growth hormone deficiency (confirmed by stimulation testing), and a handful of other diagnosed conditions [6]. It is a controlled prescription drug with tightly defined, tested uses. It is not FDA-approved for general anti-aging use, athletic performance, or weight loss in adults without diagnosed deficiency, and the FDA has taken action against marketers who imply otherwise [7]. Sermorelin is, in a sense, the gentler on-ramp: lower ceiling on effect, but also a gentler risk profile because it can't push GH past what your own pituitary allows, and it preserves the natural pulsatile release pattern rather than flooding the system. That's a real advantage for people worried about GH excess, but it's also sermorelin's weak spot: if you need a large, reliable, gland-independent GH increase (say, for confirmed severe adult GHD), sermorelin is often not strong enough on its own, and a prescriber may recommend HGH replacement instead. Sermorelin is not a stronger or superior version of HGH. It's a different tool with a lower and more self-limited ceiling.
How is sermorelin typically dosed compared to CJC-1295?
Sermorelin is usually dosed as a single subcutaneous injection at night, timed to work with the body's natural largest GH pulse during early sleep. Historical Geref dosing in pediatric GHD trials centered on daily injections at doses defined in micrograms per kilogram, typically given at bedtime [2]. In compounded-peptide clinics today, common protocols run in the range of 200 to 300 mcg per night, though exact amounts should come from a prescriber based on weight, goals, and bloodwork, not a generic chart. CJC-1295 without DAC is often dosed more like sermorelin, once daily or every other day, because its half-life is short. CJC-1295 with DAC, because it lingers in the blood for days, is typically dosed only twice a week or so in most protocols circulating in the peptide market. That lower injection frequency is the main practical selling point people cite for choosing DAC-based CJC-1295 over sermorelin. For readers who want a concrete reference point once they're working with a prescriber, the sermorelin dosage chart and sermorelin dosage calculator lay out typical starting ranges and how they're adjusted by body weight and response.
What are the side effects and safety differences?
Sermorelin's reported side effects, drawn from its clinical history as Geref and from more recent compounded-use reports, are mostly injection site reactions (redness, itching, mild swelling), flushing, headache, and occasional dizziness [2][5]. Because it respects the pituitary's own feedback loops, there's a built-in ceiling: you generally can't push GH indefinitely higher just by giving more sermorelin, because the gland's own regulatory mechanisms (including somatostatin) push back. CJC-1295, especially the DAC version, has a thinner safety record. Reported issues in user reports and limited studies include injection site reactions, flushing, water retention, joint discomfort, and increased hunger, side effects broadly similar to other GH-axis peptides, but without the depth of long-term surveillance sermorelin has from its drug-approval era. Because CJC-1295 with DAC stays active for days rather than minutes, any adverse reaction also lasts longer and is harder to simply "let wear off." Neither peptide has thorough long-term (10+ year) safety data in adults using them outside diagnosed deficiency. For a fuller rundown of what's known and unknown about extended use, see sermorelin long-term side effects.
Is CJC-1295 legal, and is sermorelin legal?
Sermorelin has a cleaner legal history because it was an FDA-approved drug (Geref) before it was discontinued commercially [2]. Pharmacies can still compound sermorelin using pharmaceutical-grade active ingredient under a prescription, following standard compounding rules enforced by state boards of pharmacy and the FDA. CJC-1295 sits in murkier territory. It was never FDA-approved, and the FDA has specifically named GHRH-related peptides, including analogs like CJC-1295, among substances that raise concerns for compounding because they don't have an approved-drug reference product or established safety and efficacy profile for compounding purposes [4]. Much of what's sold as CJC-1295 online is labeled "research use only," which is a legal gray zone: it's technically not meant for human use at all, even though that's clearly how a lot of buyers use it. This is one of the more concrete, practical differences between the two. If you want something a licensed pharmacy can compound under a real prescription with a documented regulatory history, sermorelin is the more defensible choice.
Which one is cheaper, sermorelin or CJC-1295?
Pricing varies a lot by source, dose, and whether you're going through a telehealth prescriber and licensed compounding pharmacy versus a research-chemical website. There's no single official price for either, since neither is currently sold as a branded FDA-approved product in the US. As a rough real-world range reported across compounding pharmacies and telehealth peptide clinics, sermorelin programs commonly run somewhere in the $150 to $300 per month range depending on dose and whether it's bundled with consults and labs. CJC-1295, particularly the DAC version paired with a GHRP, tends to price similarly or somewhat higher per month, partly because it's often sold as a combination product with two active peptides rather than one. Cost shouldn't be the deciding factor here. The bigger financial risk with CJC-1295 is buying from unregulated "research use only" sellers with no quality control, where you have no real guarantee of purity, concentration, or even correct identity of what's in the vial.
Can you combine sermorelin and CJC-1295, or switch between them?
Some protocols use CJC-1295 or sermorelin alongside a GHRP like ipamorelin, on the idea that hitting both the GHRH receptor and the ghrelin receptor produces a larger combined GH pulse than either alone. That combination logic is plausible mechanistically and shows up in some small pharmacology studies [3], but it hasn't been tested in large, controlled human trials for defined outcomes. Combining sermorelin and CJC-1295 with each other (rather than with a GHRP) doesn't have a clear rationale, since both act on the same GHRH receptor pathway. Stacking two GHRH analogs mostly adds cost and injection burden without a clear added benefit, and isn't something reflected in the pharmacology literature. Switching from one to the other is more common: someone who dislikes nightly sermorelin injections might move to twice-weekly CJC-1295 with DAC for convenience, or someone concerned about CJC-1295's thinner safety record might move to sermorelin for its more established profile. Either switch should go through a prescriber who can watch IGF-1 levels and adjust.
How do you decide between CJC-1295 and sermorelin?
If you want the option with real FDA history, more predictable pharmacokinetics, and a mechanism that mimics natural GH pulsing, sermorelin is the more conservative and better-supported pick. It requires more frequent injections, which some people find annoying, but that's a small tradeoff against a much better documented safety and regulatory record. If convenience (fewer injections per week) matters more to you than having an approved-drug lineage, and you're comfortable with a thinner evidence base and a murkier legal landscape around compounding, CJC-1295 is the option people choose for that reason. That's a real tradeoff, not a hypothetical one, and it should be made with eyes open. Either way, this isn't a decision to make from a peptide forum. A prescriber who orders baseline IGF-1 and other relevant labs, checks for contraindications (active cancer, uncontrolled diabetes, pregnancy), and monitors you over time is the difference between a reasonable trial and a guessing game. Sermorelin Co's role is to connect readers with that kind of provider-reviewed process rather than to sell a product directly; if you go that route, ask specifically which peptide the prescription is for and which licensed pharmacy fills it.
Where can you learn more before talking to a prescriber?
Start with the basics of how the hormone itself works and what it's approved for: the sermorelin overview page covers mechanism and evidence in more depth than fits here. If you're weighing whether compounded peptide sourcing is trustworthy, the sermorelin reviews page and sermorelin peptide near me page both address how to vet a pharmacy or clinic. For dosing specifics once you've decided sermorelin is the direction you want to go, the sermorelin dosage chart and sermorelin dosage calculator walk through typical starting points. And before starting anything long-term, read sermorelin long-term side effects so you know what to watch for over months of use, more than the first few weeks.
Frequently asked questions
Is CJC-1295 stronger than sermorelin?
Not exactly stronger, just longer-acting, especially the DAC version, which stays active in the blood for days versus sermorelin's roughly 10-20 minute half-life [1][3]. Longer action isn't the same as a bigger GH response; it mostly changes how often you need to inject, not the ceiling on how much GH your pituitary can release.
Is CJC-1295 FDA approved?
No. CJC-1295 has never received FDA approval for any human use. Sermorelin, by contrast, was FDA-approved and sold as Geref before that branded product was discontinued commercially, not withdrawn for safety reasons [2]. The FDA has also flagged CJC-1295 as a peptide of concern for compounding pharmacies [4].
Why was Geref (sermorelin) discontinued?
Geref was discontinued as a marketed product for business reasons, not because of a safety recall or FDA withdrawal for harm. It remains referenced in FDA drug databases as an approved product whose sponsor stopped marketing it [2]. Sermorelin is still available today through compounding pharmacies under prescription.
Does sermorelin work as well as HGH?
No, not in raw effect size. HGH is the hormone itself and produces a larger, more direct increase in GH and IGF-1 [5][6]. Sermorelin only works if your pituitary gland can still respond, and it produces a more modest, self-limited rise because your body's own feedback loops cap the response.
Can sermorelin replace HGH therapy?
Sometimes, for people with mild deficiency and a responsive pituitary, but not for everyone. If someone has severe adult growth hormone deficiency confirmed by stimulation testing, sermorelin alone often isn't strong enough, and a prescriber may recommend direct HGH replacement instead [6].
What is the half-life difference between CJC-1295 and sermorelin?
Sermorelin's half-life is roughly 10 to 20 minutes [1]. CJC-1295 without DAC is similar, around 30 minutes, while CJC-1295 with DAC extends to several days because it binds to albumin in the blood [3]. That difference drives how often each is injected.
Is it legal to buy CJC-1295 online?
Buying peptides labeled "research use only" for personal use sits in a legal gray area, and the FDA has raised specific concerns about compounding GHRH analogs like CJC-1295 due to lack of an approved reference drug and safety data [4]. Sermorelin has a cleaner path since it can be compounded from an active ingredient tied to a formerly approved drug.
Do sermorelin and CJC-1295 have the same side effects?
Broadly similar: injection site reactions, flushing, headache, and mild water retention show up with both [2][5]. CJC-1295, especially the DAC version, has less long-term surveillance data, so any side effect also lasts longer given its multi-day half-life.
How often do you inject CJC-1295 versus sermorelin?
Sermorelin is typically injected nightly. CJC-1295 without DAC is dosed similarly, close to daily, while CJC-1295 with DAC is usually injected only twice a week because it stays active in the blood for days rather than minutes [3].
Can you combine CJC-1295 and sermorelin?
There's no clear rationale for stacking them together since both act on the same GHRH receptor pathway; it mostly adds cost and injections without added benefit. Combining either one with a GHRP like ipamorelin (a different receptor pathway) is the pairing more commonly discussed in pharmacology literature [3].
Which is cheaper, CJC-1295 or sermorelin?
Sermorelin programs through telehealth clinics and compounding pharmacies commonly run around $150 to $300 per month; CJC-1295, especially combination products with a GHRP, often price similarly or a bit higher. Prices vary widely by source, so cost shouldn't be the deciding factor over safety and legal sourcing.
Is sermorelin safer than CJC-1295?
Sermorelin has a longer track record, an FDA approval history as Geref, and a self-limiting mechanism because it respects the body's natural feedback loops [1][2]. CJC-1295 has a thinner evidence base and murkier compounding legality, which makes sermorelin the more conservative choice for most people weighing the two.
Sources
- National Center for Biotechnology Information (NCBI Bookshelf), StatPearls: Physiology, Growth Hormone: Sermorelin is a 29-amino-acid fragment of GHRH with a short half-life and full biological activity
- U.S. Food and Drug Administration, Drugs@FDA database, Geref (sermorelin acetate) NDA 019916: Geref (sermorelin acetate) was FDA-approved and later discontinued as a marketed product
- Teichman SL, et al., "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults," Journal of Clinical Endocrinology & Metabolism, 2006, PMID 16352683: CJC-1295 with DAC produces sustained increases in GH and IGF-1 with a multi-day half-life
- U.S. Food and Drug Administration, Federal Register notice on bulk drug substances nominated for the 503A compounding bulks list: FDA has raised concerns about compounding GHRH analog peptides like CJC-1295 due to lack of approved reference drug status
- Corpas E, Harman SM, Blackman MR, "Human growth hormone and human aging," Endocrine Reviews, 1993, PMID 8325248: Growth hormone secretagogues like sermorelin produce more modest, physiologic GH elevation dependent on pituitary responsiveness
- Molitch ME, et al., "Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline," Journal of Clinical Endocrinology & Metabolism, 2011, PMID 21646368: HGH (somatropin) is used for defined indications including confirmed adult and pediatric growth hormone deficiency, per Endocrine Society guidance
- U.S. Food and Drug Administration, Consumer Update: "Human Growth Hormone and Anti-Aging": FDA has taken action against marketing of HGH for unapproved anti-aging or performance uses
- National Institute on Aging, "Growth Hormone and Aging": Growth hormone levels naturally decline with age and are one reason adults seek GH-axis therapies